Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Sofia, Bulgaria Clinical Trials

A listing of Sofia, Bulgaria clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

A Phase I study to assess the systemic exposure, effiacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) ...

Phase

0.9 miles

Learn More »

A Study of Orally Administered JNJ-56136379 to Evaluate Safety Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I) and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

Part 1: This is a first-in-human (FIH), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), randomized (study medication assigned to participants by chance), placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a ...

Phase

1.2 miles

Learn More »

A Dose Escalation Study Of PF-06801591 In Melanoma Head And Neck Cancer (SCCHN) Ovarian Sarcoma Non-Small Cell Lung Cancer Urothelial Carcinoma or Other Solid Tumors

Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung ...

Phase

1.92 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This is an open-label, multi-center, Phase 1 dose-escalation and dose expansion study to define a MTD, describe preliminary safety, and to assess PK, immunogenicity, and potential anti-tumor activity of INCMGA00012 administered on either every two week or every four week schedules in patients with relapsed/ refractory or unresectable locally/ advanced ...

Phase

1.94 miles

Learn More »

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic hepatitis B. Part I will be conducted in two portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include only healthy volunteers. ...

Phase

1.96 miles

Learn More »

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal renal function.

Phase

1.96 miles

Learn More »

A Study of JHL1101 Versus MabThera in Subjects With Severe Rheumatoid Arthritis

This study will take place across approximately 31 centres across 12 countries and will randomise approximately 150 subjects as outpatients. The primary objective is to investigate and compare the pharmacokinetic profiles of JHL1101 and MabThera (rituximab). The secondary objectives are to investigate the safety, tolerability, and immunogenicity of JHL1101 versus ...

Phase

1.96 miles

Learn More »

Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

The purpose of this international study is to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.

Phase

3.3 miles

Learn More »